Opportunity to demo the only FDA-cleared, non-invasive plaque analysis based on objective ground truth histology, the gold standard for characterization of plaques BOSTON – July 10, 2025 – Elucid, an AI medical technology company focused on providing physicians with a...
Press Releases
Elucid Appoints Dr. Robert Pelberg as New Senior Vice President of Medical Affairs
Cardiac CT Expert to Advance Research and Commercialization of Company’s PlaqueIQTM Image Analysis Software BOSTON – July 7, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive...
Elucid Adds Clinical and Commercial Leadership Ahead of PlaqueIQ™ Launch
BOSTON – March 3, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has added several senior members to its clinical and commercial teams. The...
Elucid Announces Fifth Medicare Administrative Contractor to Cover AI Coronary Plaque Analysis
Noridian latest MAC to make Elucid PlaqueIQTM image analysis software available for eligible patients BOSTON – October 25, 2024 – Elucid has announced that Noridian will extend coverage for AI-enabled quantitative coronary plaque analysis, including its FDA-cleared...
Elucid Announces Favorable Medicare Coverage of AI Coronary Plaque Analysis
New policy to make company’s PlaqueIQTM image analysis software available to eligible patients with suspected coronary artery disease BOSTON – October 15, 2024 – Elucid has announced that four of the seven Medicare Administrative Contractors (MACs) will extend...
Elucid Raises $80 Million in Series C Round Led by Elevage Medical Technologies
Investment will drive commercialization and expansion of AI-powered non-invasive diagnostic tools to help evaluate cardiovascular risk BOSTON, Nov. 9, 2023 – Elucid, a leading medical technology company providing physicians with AI-powered imaging analysis software to...
Elucid Appoints Windi Hary to Lead Regulatory Affairs and Quality Management
BOSTON, Sept. 6, 2023 – Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, has hired Windi Hary as senior vice president (SVP) of regulatory affairs and quality...
Elucid Names Scott Huennekens Executive Chairman of the Board
BOSTON, April 25, 2023 – Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, today announced that it has named Scott Huennekens executive chairman of its board of...
Andrew Miller Joins Elucid as Chief Technology Officer
BOSTON, March 28, 2023 – Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, has hired Andrew Miller as its chief technology officer (CTO). In this role, Andrew will lead...
Elucid Appoints Scott Burger as Chief Commercial Officer
Elucid, Inc., a medical technology company providing physicians AI-powered imaging analysis software to characterize cardiovascular disease, has announced that the company’s technology will be featured on the program at the 2022 American Heart Association (AHA) Scientific Sessions, November 5-7, 2022 in Chicago.